Kirkland & Ellis partners Devora W. Allon, Gilad Bendheim, Karl Gunderson and Jay P. Lefkowitz have stepped in to represent Teva Pharmaceutical in a pending antitrust class action over Lamictal tablets products. The case, filed Feb. 7 in Pennsylvania Eastern District Court by Berger Montague; Garwin Gerstein & Fisher; Faruqi & Faruqi; Heim, Payne & Chorush and other plaintiffs firms, contends that the defendants orchestrated to delay generic competition for Lamictal, a prescription drug used to treat epilepsy, bipolar disorder and other medical conditions, by GlaxoSmithKline agreeing not to launch a less expensive authorized generic version of the drug in competition with Teva. Attorneys from Troutman Pepper Hamilton Sanders are representing GlaxoSmithKline. The case, assigned to U.S. District Judge Kelley Brisbon Hodge, is 2:23-cv-00480, Morris & Dickson Co., L.L.C. v. Glaxosmithkline LLC et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector. Read the complaint here:

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]